![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRAT |
Gene summary for LRAT |
![]() |
Gene information | Species | Human | Gene symbol | LRAT | Gene ID | 9227 |
Gene name | lecithin retinol acyltransferase | |
Gene Alias | LCA14 | |
Cytomap | 4q32.1 | |
Gene Type | protein-coding | GO ID | GO:0001523 | UniProtAcc | O95237 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9227 | LRAT | HCC1 | Human | Liver | HCC | 3.83e-19 | 1.69e+00 | 0.5336 |
9227 | LRAT | HCC2 | Human | Liver | HCC | 2.22e-41 | 3.36e+00 | 0.5341 |
9227 | LRAT | HCC5 | Human | Liver | HCC | 7.62e-59 | 3.10e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
GO:000758421 | Liver | HCC | response to nutrient | 111/7958 | 174/18723 | 1.10e-08 | 2.73e-07 | 111 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
GO:000672011 | Liver | HCC | isoprenoid metabolic process | 65/7958 | 116/18723 | 2.23e-03 | 1.11e-02 | 65 |
GO:0033273 | Liver | HCC | response to vitamin | 52/7958 | 93/18723 | 6.18e-03 | 2.53e-02 | 52 |
GO:0006766 | Liver | HCC | vitamin metabolic process | 57/7958 | 106/18723 | 1.25e-02 | 4.53e-02 | 57 |
GO:003430812 | Liver | HCC | primary alcohol metabolic process | 55/7958 | 102/18723 | 1.30e-02 | 4.67e-02 | 55 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRAT | SNV | Missense_Mutation | novel | c.531G>C | p.Gln177His | p.Q177H | O95237 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
LRAT | insertion | Frame_Shift_Ins | novel | c.227_228insGCCGCCAGACCTGGTGACGCATTCGCATGTATTTAAGG | p.Asp76GlufsTer19 | p.D76Efs*19 | O95237 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
LRAT | SNV | Missense_Mutation | c.89C>T | p.Ala30Val | p.A30V | O95237 | protein_coding | tolerated(0.27) | benign(0.01) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
LRAT | SNV | Missense_Mutation | c.206G>A | p.Arg69His | p.R69H | O95237 | protein_coding | deleterious(0.02) | probably_damaging(0.915) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRAT | SNV | Missense_Mutation | novel | c.665N>C | p.Ile222Thr | p.I222T | O95237 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
LRAT | SNV | Missense_Mutation | novel | c.226G>A | p.Asp76Asn | p.D76N | O95237 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LRAT | SNV | Missense_Mutation | novel | c.533N>T | p.Ser178Phe | p.S178F | O95237 | protein_coding | tolerated(0.07) | benign(0.055) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRAT | SNV | Missense_Mutation | novel | c.425N>T | p.Ala142Val | p.A142V | O95237 | protein_coding | tolerated(0.2) | possibly_damaging(0.615) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRAT | SNV | Missense_Mutation | c.237N>T | p.Leu79Phe | p.L79F | O95237 | protein_coding | tolerated(0.06) | probably_damaging(0.914) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
LRAT | SNV | Missense_Mutation | novel | c.277N>C | p.Ser93Pro | p.S93P | O95237 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |